Mediterranean Diet and Patients With Psoriasis
JAMA Dermatology, 2025
Perez-Bootello J., Berna-Rico E., Abbad-Jaime de Aragon C., Goni L., Vazquez-Ruiz Z., Neria F., Cova-Martin R., Naharro-Rodriguez J., Ballester-Martinez A., Pindado-Ortega C., Monge D., Blauvelt A., Jaen P., Mehta N., Gelfand J., Martinez-Gonzalez M., Gonzalez-Cantero ?.
| Disease area | Application area | Sample type | Products |
|---|---|---|---|
Dermatological Diseases | Pathophysiology | Plasma |  Olink Target 96 |
Abstract
Importance
Despite growing interest on the role of diet in the prevention and treatment of psoriasis, randomized clinical trials are lacking. The Mediterranean diet is known for its anti-inflammatory and cardiometabolic benefits, which may be relevant to psoriasis pathophysiology.
Objective
To assess whether a 16-week Mediterranean diet intervention would improve psoriasis severity in patients with mild to moderate disease.
Design, Setting, and Participants
MEDIPSO (Impact of the Mediterranean Diet on Patients With Psoriasis), an open-label, single-center, single-blinded (evaluator) randomized clinical trial, was conducted from February 2024 to March 2025 at a dermatology referral clinic in Madrid, Spain. Participants were adults with mild to moderate psoriasis (Psoriasis Area and Severity Index [PASI] of 2-10, with higher scores indicating maximal disease) receiving stable topical therapy.
Interventions
Participants were randomized 1:1 to the intervention or control group. The intervention group received a 16-week, dietitian-guided Mediterranean diet program, including nutritional counseling, educational materials, and weekly provision of extra virgin olive oil. The control group received standard low-fat dietary advice without dietitian supervision.
Main Outcomes and Measures
The primary outcome was the change in the PASI from baseline to week 16. Secondary outcomes included changes in Mediterranean diet adherence, anthropometric and metabolic parameters, serum inflammatory cytokines, and patient-reported outcomes. Estimated marginal means (EMMs) at baseline and for the change from baseline to week 16 were reported, with the intervention effect presented as the between-group difference.
Results
Among 45 individuals screened, 38 participants were enrolled and randomized (mean [SD] age, 46.4 [12.8] years; 25 males [65.8%]); 19 were randomized to the intervention group and 19 were randomized to the control group; 37 individuals (97.4%) completed the study. The EMM PASI change at week 16 was −3.4 (95% CI, −4.4 to −2.4) in the intervention group and 0.0 (95% CI, −1.0 to 1.0) in the control group; the between-group EMM difference was −3.4 (95% CI, −4.8 to −2.0; P < .001). Nine of 19 participants in the Mediterranean diet group (47.4%) achieved PASI 75 (a 75% reduction in PASI) compared with none in the control group. A significant reduction in EMM hemoglobin A1c (glycated hemoglobin) was observed in the intervention group as compared with the control group (between-group EMM difference, −4.1 mmol/mol [95% CI, −6.9 to −1.3 mmol/mol]; P = .01).
Conclusions and Relevance
This randomized clinical trial found that a 16-week Mediterranean diet intervention significantly improved psoriasis severity in patients with mild to moderate disease receiving stable topical therapy. These findings suggest that incorporating dietary strategies may be beneficial as an adjunctive therapy in psoriasis management.
Trial Registration
ClinicalTrials.gov Identifier: NCT06257641